“Health is the greatest gift, contentment the greatest wealth, faithfulness the best relationship.” – Buddha
PNA Spotlight: Dr. Aaron Cohen-Gadol
This month the PNA Spotlight focuses on Dr. Aaron Cohen-Gadol, a professor at Indiana University Department of Neurosurgery. He is the director of neurosurgical oncology and its fellowship, and co-director of the Signature Center for Brain and Neurological Tumors. Dr. Cohen-Gadol earned his undergraduate degree from the University
of California at San Diego and attended medical school at the University of Southern California. He then completed his residency training at Mayo Clinic in Rochester, Minnesota. He also completed fellowship training in two subspecialties: epilepsy surgery (Yale University) and skull base/cerebrovascular surgery (University of Arkansas.) In addition, Dr. Cohen holds a Master’s Degree in Clinical Research from Mayo Graduate School and an MBA from Kelley School of Business. His areas of interest include surgical treatment of complex intracranial tumors and vascular lesions.
He is the founder and president of The Neurosurgical Atlas (http://www.neurosurgicalatlas.com), a multimedia resource for neurosurgical techniques. Dr. Cohen-Gadol was kind enough to answer some questions posed by the PNA. His answers follow.
Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support
Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.
Sign up to get dedicated support:
Patients: Sign up for support | Recorlev® (levoketoconazole)
HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)
Have more questions? Call for more support at 1-844-444-RCLV (7258)
PNA Medical Corner: Somatotroph Adenoma in a Young Adult
This month the PNA Medical Corner spotlights an article co-authored by a member of the PNA, Dr. Ursula Kaiser, Chief of the Division of Endocrinology, Diabetes and Hypertension at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. The case report looks at early onset excess of growth hormone in the context of a somatotroph adenoma in a young adult.
Link: https://doi.org/10.1210/jcemcr/luad030
Early Onset GH Excess: Somatotroph Adenoma in a Young Adult
Featured News and Updates
The FDA has approved NGENLA (somatrogon-ghla)
The FDA has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.
News Articles July 2024
Hormonal Disruptions and Pituitary Tumors
An endocrinologist in India discusses the hormonal disruption experienced by pituitary patients. Read more: https://www.hindustantimes.com/lifestyle/health/hormonal-disruptions-caused-by-pituitary-tumours-endocrinologist-shares-insights-101718974544057.html
Novel Cushing’s Treatment in Phase 2 Trials
The pharmaceutical company Lundbeck is now in Phase 2 clinical trials to assess a “potential first-in-class” treatment for Cushing’s disease called LuAG13909. Read more:
Pain in Men vs Women: The Role of Hormones
An article in Very Well Health looks at a study on how pain is produced and felt in women versus men. The researchers found that the hormone prolactin lowered the threshold to activate specialized sensory cells called nociceptors in female cells but did not in male cells. However the neuropeptide orexin B had the opposite effect. This could have implications for pain management, as women make up a large percentage of patients seeking treatment for pain. Read more:
https://www.verywellhealth.com/women-and-men-have-differences-in-pain-production-8665947
Hormonal Disruptions and Pituitary Tumors
An endocrinologist in India discusses the hormonal disruption experienced by pituitary patients. Read more: https://www.hindustantimes.com/lifestyle/health/hormonal-disruptions-caused-by-pituitary-tumours-endocrinologist-shares-insights-101718974544057.html
Research Articles
July 2024 Research Articles
Pituitary Tumors
Genome-Wide DNA Methylation Profiling as a Prognostic Marker in Pituitary Adenomas-A Pilot Study.
Møller MW, Andersen MS, Halle B, Pedersen CB, Boldt HB, Tan Q, Jurmeister PS, Herrgott GA, Castro AV, Petersen JK, Poulsen FR.Cancers (Basel). 2024 Jun 13;16(12):2210. doi: 10.3390/cancers16122210.
Zhu Z, Hu B, Zhu D, Li X, Chen D, Wu N, Rao Q, Zhang Z, Wang H, Zhu Y.J Endocrinol Invest. 2024 Jun 26. doi: 10.1007/s40618-024-02408-0. Online ahead of print.
Chiari I Malformation With Concomitant Nonfunctioning Pituitary and Adrenal Tumors.
Zielinski R, Khan A, Mirza FS.JCEM Case Rep. 2024 Jun 25;2(6):luae113. doi: 10.1210/jcemcr/luae113. eCollection 2024 Jun.
Pituitary Surgery
Adams OE, Olson SB, Lam H, Judge C, McClelland C, Lee MS, Venteicher AS.Neuroophthalmology. 2024 Jan 26;48(4):272-278. doi: 10.1080/01658107.2023.2299763. eCollection 2024.
Kemchoknatee P, Singhakul C, Arjkongharn N, Vongsa N, Tangon D, Srisombut T.Clin Ophthalmol. 2024 Jun 21;18:1779-1788. doi: 10.2147/OPTH.S463303. eCollection 2024.
Acromegaly
Personalized medicine in acromegaly: The ACROFAST study.
Marques-Pamies M, Gil J, Sampedro-Nuñez M, Valassi E, Biagetti B, Giménez-Palop O, Hernández M, Martínez S, Carrato C, Villar-Taibo R, Araujo-Castro M, Blanco C, Simón-Muela I, Simó-Servat A, Xifra G, Vázquez F, Pavón I, Rosado JA, García-Centeno R, Zavala R, Hanzu FA, Mora M, Aulinas A, Vilarrasa N, Librizzi S, Calatayud M, de Miguel P, Alvarez-Escola C, Picó A, Salinas I, Fajardo-Montañana C, Cámara R, Bernabéu I, Jordà M, Webb SM, Marazuela M, Puig-Domingo M.J Clin Endocrinol Metab. 2024 Jun 29:dgae444. doi: 10.1210/clinem/dgae444. Online ahead of print.
Glucose metabolism outcomes after pituitary surgery in patients with acromegaly.
Pascual-Corrales E, Biagetti B, Marazuela M, Asensio-Wandosel D, Rodríguez Berrocal V, Irigaray Echarri A, Novo-Rodríguez C, Calatayud M, Bernabéu I, Alvarez-Escola C, Tenorio-Jiménez C, González Molero I, Iglesias P, Blanco C, de Miguel P, López Mezquita E, Lamas C, Aulinas A, Gracia P, Recio-Córdova JM, Sampedro-Nuñez M, Paja M, Moure Rodríguez MD, Fajardo-Montañana C, Cordido F, Menéndez Torre E, Percovich JC, García-Centeno R, Cámara R, Hanzu FA, Vicente Delgado A, González Fernández L, Guerrero-Pérez F, Ollero García-Agulló MD, Novoa-Testa I, Villar-Taibo R, Benítez Valderrama P, Abellán Galiana P, Venegas Moreno E, Vidal-Ostos De Lara F, Enseñat J, Aznar S, Asla Q, Aviles-Pérez MD, Puig-Domingo M, Araujo-Castro M. Pituitary. 2024 Jun 28. doi: 10.1007/s11102-024-01415-x. Online ahead of print.
Cardiac MRI in acromegaly: looking for a big heart.
Schweizer JROL, Nachtigall LB.Pituitary. 2024 Jun 28. doi: 10.1007/s11102-024-01417-9. Online ahead of print.
Risk of intracranial meningioma in patients with acromegaly: a systematic review.
Guo AX, Job A, Pacione D, Agrawal N.Front Endocrinol (Lausanne). 2024 Jun 11;15:1407615. doi: 10.3389/fendo.2024.1407615. eCollection 2024.
Obstructive Sleep Apnea Screening and Effects of Surgery in Acromegaly: A Prospective Study.
Cho J, Kim JH, Kim YH, Lee J.Endocrinol Metab (Seoul). 2024 Jun 26. doi: 10.3803/EnM.2024.1933. Online ahead of print.
Pituitary tumor centers of excellence (PTCOE): the next border of acromegaly treatment.
Grottoli S, Ghigo E.Pituitary. 2024 Jun 25. doi: 10.1007/s11102-024-01416-w. Online ahead of print.
Pituitary Apoplexy
Pituitary apoplexy: a systematic review of non-gestational risk factors.
Kajal S, Ahmad YES, Halawi A, Gol MAK, Ashley W.Pituitary. 2024 Jun 27. doi: 10.1007/s11102-024-01412-0. Online ahead of print.
Mullins J, Bryniarski M.Cureus. 2024 May 28;16(5):e61259. doi: 10.7759/cureus.61259. eCollection 2024 May.
Hormonal Health
Evaluation and Surgical Management of Multiple Endocrine Neoplasias.
Frye CC, Brown TC, Olson JA Jr.Surg Clin North Am. 2024 Aug;104(4):909-928. doi: 10.1016/j.suc.2024.02.016. Epub 2024 Apr 4.
Identification of the FSH-RH as the other gonadotropin-releasing hormone.
Uehara SK, Nishiike Y, Maeda K, Karigo T, Kuraku S, Okubo K, Kanda S.Nat Commun. 2024 Jun 27;15(1):5342. doi: 10.1038/s41467-024-49564-8.
Prevention of Male Late-Onset Hypogonadism by Natural Polyphenolic Antioxidants.
Martin LJ, Touaibia M.Nutrients. 2024 Jun 9;16(12):1815. doi: 10.3390/nu16121815.
Roux A, Rosso D, Cuboni D, Maccario M, Grottoli S, Arvat E, Gasco V.Biomedicines. 2024 Jun 19;12(6):1368. doi: 10.3390/biomedicines12061368.
Copyright © 2024 Pituitary Network Association All rights reserved.
Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.
Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email info@pituitary.org
You are receiving this Newsletter because you have shown interest in receiving information about our activities.
If you do not want to receive any more emails from PNA, Unsubscribe.
